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Abstract: We aimed to determine the ability of partial nephrectomy to prevent end-stage
renal disease and tumor recurrence or progression in patients with upper tract urothelial
carcinoma. Retrospectively, eight patients undergoing partial nephrectomy for upper tract
urothelial carcinoma were identiﬁed and their medical records reviewed. All patients had
imperative indications for nephron sparing, and diagnosis of upper tract urothelial carcinoma
not adequately amenable to endoscopic management. Although three patients suffered
acute tubular necrosis, only one required postoperative hemodialysis. During the follow-up
period 25% (2/8) developed end-stage renal disease, including the one patient who had
received postoperative hemodialysis. Recurrences occurred in ﬁve of seven patients with
adequate oncological surveillance. Recurrences were successfully treated endoscopically in
80% (4/5) patients, and one patient had metastases. Of the eight patients, four have died.
Death occurred 4 months, 1 year, 1.2 years and 3.5 years after partial nephrectomy. Of these
patients, one succumbed to metastatic disease; the exact cause of death is unknown in the
other three, but there was no documentation of metastatic cancer. The mean duration of
follow up in the remaining four patients, all without evidence of metastatic urothelial cancer,
is 71 months (range 22–108 months). In summary, partial nephrectomy for upper tract
urothelial carcinoma in patients with imperative indications averts end-stage renal disease in
most patients, and appears to be associated with acceptable disease-speciﬁc survival. Partial
nephrectomy is a sparingly used option in patients with upper tract urothelial carcinoma
refractory to endoscopic management who have imperative indications for nephron sparing.
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Introduction
UTUC represents 5% of urothelial tumors.1,2 NUx is the standard treatment, but in some cases
nephron sparing is indicated. Endoscopy is effective for low-grade, superficial disease, and in
some more advanced tumors.3–6 If endoscopic treatment fails or is not possible, then the only way
to spare nephrons is to carry out partial nephrectomy.7–10 The ability of open surgical partial
nephrectomy to prevent ESRD and tumor recurrence or progression in patients with UTUC is not
well-defined.
Methods
Eight patients undergoing open surgical partial nephrectomy for UTUC from March 1997
through May 2011 at The University of Michigan Health System, Ann Arbor, USA, by one of
four attending urologists were identified. Through a combination of inspection of radiographs,
palpation and intraoperative ultrasonography, the line of incision in the renal parenchyma was
identified. After intravenous mannitol, the renal hilum was clamped and ice slush was applied.
The renal tissue was incised, and the collecting systems in both the resected and remaining
portions of the kidney were inspected, adding flexible nephroscopy if required. The collecting
system and renal parenchyma were closed and the hilar clamp was removed.
The amount of parenchyma removed was estimated by the number of calyces excised. Each of
the major calyces was counted as one-third of the renal parenchyma, except in case of
heminephrectomy, in which case it was estimated that 50% was left remaining.
With institutional review board approval, medical records were retrospectively reviewed. The
age-adjusted CCI, excluding the diagnosis of urothelial cancer, was calculated.11 Postoperative
complications were categorized using the modified Clavien system.12 The eGFR was determined
using the Modification of Diet in Renal Disease Study equation.13
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Bivariate comparisons of outcomes between groups were
limited to two outcome levels per variable, using the Fisher’s
exact test.
Results
Table 1 contains the patient demographics. In the six men and
two women, the mean age was 75 years. Overall, the patients
had considerable medical comorbidities, with a mean CCI of
4.75. Of the patients, four had a solitary kidney, with three
having undergone contralateral NUx for UTUC, and one having
a congenitally solitary kidney. Endoscopic urothelial treatment
had been carried out in seven patients. Endoscopy was unsuc-
cessful in four patients; and in three patients, high-volume
recurrence had followed initially successful endoscopic treat-
ment. The one patient without prior endoscopic treatment had
an UTUC lesion that was deemed most suitable for open
surgery (2.5 cm proximal ureteral tumor subtending lower pole
moiety of completely duplicated system). Tumor size ranged
from 1.4 to 8 cm (mean 3.5 cm).
Tumor characteristics are listed in Table 2. All patients had
confirmed urothelial cancer, high-grade in all but two. T stage
was Ta in four, Tis in one and T2 in three patients. None had
carcinoma in situ. All surgical margins were negative. None of
the five patients undergoing regional lymphadenectomy had
lymph node metastases.
The mean operative time was 238 ± 36 min (range 186–269).
The mean ischemia time was 43 min (range 15–66 min). The
mean estimated blood loss was 400 mL (range 150–850 mL).
The mean duration of hospitalization was 7 days (range 3–9
days). Of the eight patients, seven experienced postoperative
complications, with a mean Clavien score of 2.5 (range 0–4a),
includingATN in three, surgical site infections in three, ileus in
one, cerebral-vascular accident in one, seizures in one, upper
tract obstruction in one and urine leak in one patient.
Table 3 shows renal function outcomes. The mean amount of
renal parenchyma remaining was 58%. Mean follow up was 40
months (range 4–108 months). Of the patients, two progressed
to ESRD after surgery. Of these two patients, one (patient 1,
with 33% remaining parenchyma) had a serum creatinine of
4.1 mg/dL (compared with 1.8 mg/dL preoperatively) 1 year
after surgery, but then developed acute renal failure and unre-
coverable ESRD when an obstructing ureteral tumor later
developed. The other patient (patient 5, with 66% remaining
parenchyma), developed ATN postoperatively requiring tempo-
rary hemodialysis, initially recovered renal function, and then
developed ESRD. No other patient required hemodialysis post-
operatively. Eventual ESRD was not associated with the
amount of remaining parenchyma (P = 1.0) or preoperative
eGFR (P = 0.43), but it was associated with a postoperative
event impacting renal function (ureteral obstruction in patient
Table 1 Characteristics of patients undergoing partial nephrectomy for UTUC
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Age at operation (years) 75 69 74 75 74 75 80 78
Sex Male Female Female Male Male Male Male Male
Body mass index 25.7 36.2 32.3 32.8 21.1 25.7 - 31
Diabetes mellitus Yes
Hypertension Yes Yes Yes Yes Yes Yes
Coronary artery disease Yes Yes Yes Yes Yes
Tobacco use Yes Yes Yes Yes
Pre-operative eGFR 45 90 72 72 34 79 44 16
CCI 3 3 6 4 7 6 6 3
Anatomically solitary kidney Yes Yes (horseshoe
kidney)
Yes Yes
Unsuccessful endoscopic
treatment
Yes Yes Yes Yes
High volume UTUC recurrence Yes Yes Yes
Other indication for partial
nephrectomy
Poor function
contralateral
kidney
Upper urinary
tract duplication
Poor function
contralateral
kidney
Table 2 Tumor characteristics
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Location of tumor Upper
calyces
Upper calyces Lower calyces
into ureter
Renal pelvis of
left moiety
Lower
calyces
Upper
calyces
Upper
calyces
Upper and
middle calyces
Tumor size (cm) 1.4 4 3.2 4 1.4 2.2 8
pT stage pTa pT2 pT2b Ta T2 Ta Ta Tis
pN stage Negative Negative Negative Negative Negative
Grade High High High High Low Low High High
Other pathological
ﬁndings
Angiolymphatic
Invasion
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1, and transient acute tubular necrosis requiring temporary
hemodialysis in patient 5; P = 0.04).
Oncological follow up is summarized in Table 4. Of the eight
patients, there is no information about cancer recurrence in one
patient (patient 5). Of the remaining seven patients, two (29%)
have had no recurrence of urothelial carcinoma, with follow up
of 4 and 87 months (patients 7 and 4, respectively). Urothelial
tumors recurred in the bladder in patient 3 9 months after
surgery, and the last follow up was 12 months after surgery.
There were 11 recurrences in the ureter and/or bladder in
patient 6, beginning 15 months after partial nephrectomy and
continuing to be detected at each follow up, with the last follow
up 9 years after surgery. Patient 8 had three recurrences of
urothelial cancer in the bladder, at 1, 3 and 6 months after
partial nephrectomy, with the last follow up 39 months
after surgery. Patient 1 had a ureteral recurrence 12 months
after partial nephrectomy, and then subsequently developed
lung metastases, so the ureteral recurrence was palliated with a
ureteral stent until he succumbed to metastatic disease 2 years
after surgery. Patient 2 developed multifocal unresectable recur-
rences in the bladder and renal pelvis at 11 months after
surgery, and then underwent completion NUx after neo-
adjuvant chemotherapy.
Of the eight patients, four have died. Death occurred 4
months, 1 year, 1.2 years and 3.5 years after partial nephrec-
tomy. The exact cause of death was unknown in three patients,
but there was no documentation of metastatic cancer. One
patient succumbed to metastatic disease after 14 months. The
mean duration of follow up in the remaining four patients, all
without evidence of metastatic urothelial cancer, was
71 months (range 22–108 months). Death from any cause was
not associated with preoperative eGFR (P = 0.49) or ESRD
(P = 1.0).
Discussion
Our institutional experience includes eight patients receiving
open surgical partial nephrectomy due to UTUC. At the time of
publication, three of eight patients (38%) remain alive and
disease-free, with only one having died as a result of metastatic
UTUC recurrence, and one is alive but undergoing neo-
adjuvant chemotherapy.
Of our eight patients, two (25%) developed ESRD in the
follow-up period. ESRD was associated with ATN, low percent
of renal parenchyma remaining, and high Clavien score of IVa
and IV. In the remaining five patients (71%) for whom
follow-up data was available, hemodialysis was not required
throughout the follow-up period. The successful avoidance of
ESRD is notable, as ESRD has a significantly negative impact
on survival and quality of life.14,15
The 1-, 5- and 7-year survival for patients aged >65 years
beginning dialysis has been reported as 81%, 30% and 15%,
respectively.16 Munshi et al. showed that in patients aged >75
years, dialysis survival is even more truncated.17 The total
1-year survival for our series was seven out of eight (88%). Of
the patients who were followed up for >3 years, three of the
three (100%) were still alive.
In conclusion, partial nephrectomy for UTUC in patients
with imperative indications results in a high rate of preventing
Table 3 Renal function after partial nephrectomy for UTUC
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Renal ischemia time (min) 40 46 15 none 55 40 66 38
% parenchyma remaining 33% 66% 66% 50% 66% 66% 50% 66%
Preoperative eGFR 45 90 72 72 34 79 44 16
Serum creatinine levels (mg/dL)
Pre-operative 1.8 1.0 1.2 1.2 2.3 1.1 1.8 4.4
1 day postoperative 3.2 1.0 1.0 1.3 3.1 4.7
2 days postoperative 3.9 0.9 0.8 1.3 5.1 6.4
3 days postoperative 4.3 1.0 0.9 1.4 4.7 5.5
1 week postoperative 4.2 1.1 1.3 0.9 ‡ 1.4 6.2 4.2
1 month postoperative 3.4 1.2 0.9 1.0 3.9 0.9 2.0
1 year postoperative 4.1 1.2 0.9 † 0.9
Latest available † 1.2 0.8 0.9 1.5 4.5
Weeks until latest available creatinine 52 41 374 451 97
†Permanent ESRD. ‡Temporary hemodialysis.
Table 4 Oncological outcome after partial nephrectomy for UTUC
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Months of follow up 14 22 12 84 108 4 42
Local recurrence Ureter Renal/bladder Bladder None Ureter/bladder None Bladder
Metastases Yes No No No No No No
Death from UTUC Yes No No No No No No No
Any death Yes No Yes No No No Yes Yes
Partial nephrectomy for UTUC
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ESRD, and appears to be associated with acceptable disease-
specific survival. In this small cohort, we could not identify any
preoperative factors that were associated with the eventual
onset of ESRD or death. Partial nephrectomy is a reasonable
option in patients with UTUC refractory to endoscopic man-
agement who have imperative indications for nephron sparing.
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